Results 171 to 180 of about 21,108 (240)

Metabolic remodeling and cardiac functional adaptation mediated by dapagliflozin in patients with acute heart failure: a retrospective cohort study. [PDF]

Front Pharmacol
Liu F, Liu X, He Y, Liu G, Lan T, Zhao Z, Yang F.   +6 more
europepmc   +1 more source

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9573-9583, October 2026.
ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J. Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, Luke Sheridan Rains, Amanda I. Adler, Lesley Owen   +12 more
wiley   +1 more source

Dapagliflozin effects on right ventricular function, pulmonary pressure and coupling: a propensity score analysis from the RIVED-HF. [PDF]

ESC Heart Fail
Palazzuoli A, Ruocco G, Franceschi S, Schirò G, Petrini A, Manetti N, Salzano A, Severino P, Guazzi M, Crisci G, Barillà F, Mariano E, Dini FL, Di Santo M, Filardi PP, Sorrentino G, Ghio S, Rosano GMC, Italian Heart Failure Study Group, Italian Society of Cardiology and the RIVED-HF investigators.   +19 more
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8812-8824, October 2026.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Bayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin. [PDF]

CPT Pharmacometrics Syst Pharmacol
Mikhailova A, Peskov K, Helmlinger G, Sokolov V.   +3 more
europepmc   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9412-9422, October 2026.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source

Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Meng Z, Wu H, Miao Y, Qi W, Sha M.
europepmc   +1 more source

Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9518-9534, October 2026.
ABSTRACT Background The role of histone lactylation in diabetes associated renal fibrosis remains poorly defined. In this study, we investigated the contribution of histone H4 lysine 12 lactylation (H4K12la) to abnormal glycolysis and renal fibrogenesis in diabetic kidney disease (DKD) and evaluated sodium butyrate (NaB) as a potential therapeutic ...
Ping He, Mingxiu Wang, Hang Mei, Yue Liu, Min Wang, He Sun, Yali Peng, Xuan Ban, Yue Wang, Xiaofang Tang, Qiuling Fan   +10 more
wiley   +1 more source

Dapagliflozin Attenuates Pericardial Adipose Tissue-Derived Leptin-Mediated Myocardial Remodeling in Obese Rats. [PDF]

J Am Heart Assoc
Luo C, Luo W, Zheng T, Wang P, Cao L, Luan H, Song Y, Li X, Tian G.   +8 more
europepmc   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source